SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cohance Lifesciences rises on getting nod to make $10 million investment in NJ Bio Inc

03 Dec 2025 Evaluate

Cohance Lifesciences is currently trading at Rs. 549.70, up by 3.50 points or 0.64% from its previous closing of Rs. 546.20 on the BSE.

The scrip opened at Rs. 549.05 and has touched a high and low of Rs. 557.70 and Rs. 541.00 respectively. So far 17892 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1337.85 on 09-Dec-2024 and a 52 week low of Rs. 541.00 on 02-Dec-2025.

Last one week high and low of the scrip stood at Rs. 578.40 and Rs. 541.00 respectively. The current market cap of the company is Rs. 20928.34 crore.

The promoters holding in the company stood at 57.49%, while Institutions and Non-Institutions held 27.34% and 15.17% respectively.

Cohance Lifesciences has received approval for the fund infusion by way of investment in compulsorily convertible preferred stock of NJ Bio Inc, USA, a subsidiary of the company, upto an amount of $10 million. The fund when deployed will be used by the said subsidiary to support its growth initiatives including capex.

The board of directors of the company in its meeting held on December 02, 2025 considered and approved the same.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.

Cohance Lifesciences Share Price

362.55 -6.80 (-1.84%)
21-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.50
Dr. Reddys Lab 1221.45
Cipla 1230.00
Zydus Lifesciences 930.90
Lupin 2323.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×